| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
N6-Methyl-dA phosphoramidite does not have a specific biological target as it is a synthetic building block for oligonucleotide synthesis. Its role is to serve as a protected N6-methyl-2'-deoxyadenosine monomer for the synthesis of modified oligonucleotides. The N6-methyl modification on the adenine base is an important epigenetic mark (m6A) that can be incorporated into synthetic DNA for research purposes.
|
|---|---|
| ln Vitro |
In vitro activity is not applicable to N6-methyl-dA phosphoramidite as it is a synthetic intermediate. Its utility is demonstrated in its ability to be incorporated into oligonucleotides through solid-phase synthesis. The compound enables the preparation of modified oligonucleotides containing N6-methyladenine for research into epigenetics, gene regulation, and nucleic acid interactions.
|
| ln Vivo |
In vivo activity is not applicable to N6-methyl-dA phosphoramidite as it is a chemical reagent for research use only, not a therapeutic agent. The compound is not intended for administration to living organisms.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not performed for N6-methyl-dA phosphoramidite, as it is a synthetic intermediate. Its characterization typically involves chemical analysis methods such as HPLC, NMR, and mass spectrometry to confirm identity and purity.
|
| Cell Assay |
In vitro cellular assays are not applicable to N6-methyl-dA phosphoramidite. The compound is used exclusively in chemical synthesis reactions for the production of modified oligonucleotides, which can subsequently be used in cellular assays to study the effects of N6-methyladenine modifications on gene expression and nucleic acid interactions.
|
| Animal Protocol |
In vivo animal experiments are not applicable to N6-methyl-dA phosphoramidite. The compound is a research chemical used in oligonucleotide synthesis and is not intended for in vivo administration.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data are not applicable to N6-methyl-dA phosphoramidite as it is a synthetic intermediate, not a therapeutic agent. The compound is not intended for systemic administration. It has a molecular weight of 767.85 and a molecular formula of C41H50N7O6P.
|
| Toxicity/Toxicokinetics |
Toxicological data for N6-methyl-dA phosphoramidite are not applicable as it is a research chemical. The compound is intended for research use only and is not for human therapeutic application. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
N6-Methyl-dA phosphoramidite (CAS#: 105931-58-6) has the molecular formula C41H50N7O6P and a molecular weight of 767.85. It is used in the synthesis of oligodeoxyribonucleotides containing N6-methyladenine modifications. The compound is for research use only.
|
| Molecular Formula |
C41H50N7O6P
|
|---|---|
| Molecular Weight |
767.85
|
| Exact Mass |
751.361
|
| CAS # |
105931-58-6
|
| PubChem CID |
86280297
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
862.0±75.0 °C at 760 mmHg
|
| Flash Point |
475.1±37.1 °C
|
| Vapour Pressure |
0.0±3.3 mmHg at 25°C
|
| LogP |
8.48
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
18
|
| Heavy Atom Count |
55
|
| Complexity |
1160
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CC(C)N(C(C)C)P(OCCC#N)O[C@H]1C[C@@H](O[C@@H]1COC(C2=CC=CC=C2)(C3=CC=C(C=C3)OC)C4=CC=C(C=C4)OC)N5C=NC6=C(N=CN=C65)NC
|
| InChi Key |
PTWRBAYAPDVZGR-JNTXQERPSA-N
|
| InChi Code |
InChI=1S/C41H50N7O6P/c1-28(2)48(29(3)4)55(52-23-11-22-42)54-35-24-37(47-27-46-38-39(43-5)44-26-45-40(38)47)53-36(35)25-51-41(30-12-9-8-10-13-30,31-14-18-33(49-6)19-15-31)32-16-20-34(50-7)21-17-32/h8-10,12-21,26-29,35-37H,11,23-25H2,1-7H3,(H,43,44,45)/t35-,36+,37+,55?/m0/s1
|
| Chemical Name |
3-[[(2R,3S,5R)-2-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-5-[6-(methylamino)purin-9-yl]oxolan-3-yl]oxy-[di(propan-2-yl)amino]phosphanyl]oxypropanenitrile
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 250 mg/mL (325.58 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3023 mL | 6.5117 mL | 13.0234 mL | |
| 5 mM | 0.2605 mL | 1.3023 mL | 2.6047 mL | |
| 10 mM | 0.1302 mL | 0.6512 mL | 1.3023 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
